Cited by 38Parkinson's Disease Mechanisms and TreatmentsNeuroinflammation and Neurodegeneration MechanismsNuclear Receptors and Signaling

Leucine-rich repeat kinase 2 modulates cyclooxygenase 2 and the inflammatory response in idiopathic and genetic Parkinson's disease

Open access
Lopez de Maturana, Rakel, Aguila, Julio C., Sousa, Amaya, Vazquez, Nerea, del Rio, Patricia, Aiastui, Ana, Gorostidi, Ana, Lopez de Munain, Adolfo +1 more·2014·Neurobiology of Aging

Abstract

Inflammatory mechanisms are activated in aging and late-onset neurodegenerative diseases, such as Parkinson's disease (PD). Mutations in leucine-rich repeat kinase 2 (LRRK2) contribute to both idiopathic and familial forms of PD. Here, we investigated the involvement of LRRK2 in inflammatory pathways using primary dermal fibroblasts from patients with 2 common mutations in LRRK2 (G2019S and R1441G), idiopathic PD and age-matched healthy individuals. Basal cyclooxygenase (COX)-2 RNA levels were very high in the fibroblasts of all patients. Remarkably, LRRK2 silencing experiments significantly reduced basal COX-2 levels and COX-2 induction after a pro-inflammatory stimulus. Additionally, in samples from patients with the R1441G mutation and with idiopathic PD, we found a prominent cytoplasmic re-distribution of human antigen R, a protein that, among others, stabilizes COX-2 RNA. Furthermore, the response to lipopolysaccharide was defective in these 2 groups, which showed weak induction of pro-inflammatory cytokines and reduced NFκB transcriptional activation. In summary, we describe multiple defects in inflammatory pathways in which LRRK2 appears to be critically involved. Further studies are required to establish the therapeutic implications of inflammatory dysregulation in the pathophysiology of Parkinson's disease.

Integrity signals

Registry

Crossref · 10.1016/j.neurobiolaging.2013.11.018

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Epidermal cells obtained from PD patients with the LRRK2-G2019S mutation showed a blunted response to LPS treatment compared to control cells.

    “In agreement with our findings, a recent study reported that epidermal cells obtained from PD patients with the LRRK2-G2019S mutation showed a blunted response to LPS treatment compared to control cells (65).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Lopez de Maturana, R., Aguila, J. C., Sousa, A., Vazquez, N., del Rio, P., Aiastui, A., Gorostidi, A., Lopez de Munain, A., & Sanchez-Pernaute, R.
Affiliations
Biogipuzkoa Health Research Institute (ES)
Venue
Neurobiology of Aging
Publisher
Elsevier BV
Published
2014-05
Volume
35
Issue
5
Pages
1116-1124
ISSN
0197-4580 (ISSN-L)
OpenAlex
W2083760444
Cited by
38
References
1
Citations by year
2026: 2 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 5 · 2019: 2 · 2018: 3 · 2017: 3 · 2016: 8 · 2015: 2 · 2014: 7
FWCI
3.60
Type
journal article
Language
en
Open access
Locations
  • Neurobiology of Aging (publishedVersion)
  • PubMed (publishedVersion)
  • Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, other-oa)
Funders
  • Departments of Industry (S-PE10IB04)
  • Education of the Basque Government (EC2011/47)
  • European Commission (DDPDGENES RR 278871-2)
  • ISCIII, Spanish Ministry of Economy and Competitiveness, and Health Research Biodonostia Institute (CA00/01506)
  • FPI (BES-2009-028305)
Topics
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nuclear Receptors and Signaling
Keywords
LRRK2, cyclooxygenase-2, Parkinson's disease, neuroinflammation, LRRK2 mutations, dermal fibroblasts, HuR, lipopolysaccharide response, inflammatory cytokines, NF-κB activation, familial Parkinson's disease
MeSH terms
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Aged, Aged, 80 and over, Cells, Cultured, Fibroblasts, Humans, Inflammation, Middle Aged, Mutation, Parkinson Disease, RNA, Transcriptional Activation, NF-kappa B, Protein Serine-Threonine Kinases, Cyclooxygenase 2, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review